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Objectives. To validate the Australian Vascular Quality of Life Index (AUSVIQUOL) as a quality of life (QOL) tool
appropriate for peripheral vascular disease patients in the clinical setting.
Design. Cross-sectional study.
Materials. The study group consisted of 71 patients with vascular claudication of varying severity attending a tertiary
hospital outpatient department.
Methods. The results of the AUSVIQUOL and Medical Outcomes Short Form Health Survey (SF-36) were compared
through factor and regression analyses. A group of 12 patients was then reassessed to compare the reliability and internal
consistency of the two indices.
Results. The AUSVIQUOL took less time to complete than the SF-36 (3.27 v 10.79 min; p< 0.0001) and fewer patients
found the questions confusing (2% v 26%). The AUSVIQUOL was easier to administer and had a higher level of patient
acceptance than the SF-36. The regression analysis showed that for each of the domains in the AUSVIQUOL there was
a significant correlation with measures in the SF-36 (adjusted R-squared 0.420, 0.480 and 0.331). The AUSVIQUOL
demonstrated a good level of internal consistency when compared to the SF-36 (Cronbach’s alpha 0.8702 vs 0.6307).
Conclusion. In comparison with the SF-36, the AUSVIQUOL is an improved tool for the QOL assessment of patients
with peripheral vascular disease in the clinical setting.
Keywords: Peripheral Vascular Disease (PVD); Quality of Life (QOL); Medical Outcomes Short Form Health Survey
(SF-36); Claudication.Introduction
The practice of medicine is undergoing continual
change and development. In the last century, there
has been a significant shift in emphasis from curative
medicine alone to quality of life health outcomes. This
is embodied in the World Health Organisation’s defi-
nition of health; a state of physical, social and mental
well-being and not simply an absence of infirmity.1
A majority of QOL indices are generic and are
designed to assess all areas of disease-associated
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measure of the relative burden of illness in the general
population,2 however, this can make them time
consuming and arduous for patients to complete. Fur-
thermore, generic indices lack sensitivity3,4 and may
not adequately assess QOL in patients with a specific
chronic disease process where many of the questions
may be irrelevant, unnecessary and repetitive. Hence,
disease-specific QOL indices are now being devel-
oped for use in various disciplines of medicine and
surgery. These disease-targeted instruments may be
used to elucidate specific domains of particular
importance to the patient.
Health-related QOL is significantly impaired in
individuals with peripheral vascular disease. Inter-
mittent claudication refers to leg pain consistently
produced by walking, and is relieved by rest. This
impacts on QOL in several ways, including pain,
sleep disturbance and restrictions in activities of dailyrved.
200 M. J. Smith et al.living.5 Patients also demonstrate significant impair-
ment in social, emotional and mental health.3 QOL
as an outcome measure in the management of periph-
eral vascular disease is especially important because
intervention, including conservative or invasive mea-
sures, aim to improve quality rather than quantity of
life.3 Studies have shown that the severity and nature
of occlusive peripheral vascular symptoms and the
response to treatment are more adequately assessed
by a disease-specific QOL measure.3,4,6 Examples of
measures currently available include the VascuQol7
and the Claudication Scale (CLAU-S).8
The Australian Vascular Quality of Life Index was
developed as a QOL index specific for vascular
disease patients.9 It was first validated in abdominal
aortic aneurysm (AAA) patients,9 yet the question
areas are relevant to all fields of vascular surgery.
The aim of the present study was to demonstrate
this QOL index as an appropriate tool for patients
with vascular claudication.
Materials and Methods
Patients
The prospective study group consisted of seventy-one
patients with intermittent claudication due to peri-
pheral vascular disease attending the Royal Perth Hos-
pital (RPH) outpatient vascular clinic. The inclusion
criteria were patients with the symptom of claudica-
tion of varying severity, secondary to peripheral
vascular disease. They were recruited consecutively
over a 3-month time period. Patients who were non-
English speaking or with diagnosed dementia were
excluded. No patient refused to participate.
In order to validate the AUSVIQUOL against the
SF-36 for use in vascular patients, patients were asked
to complete both questionnaires with or without assis-
tance. The SF-36 was presented first, then the AUSVI-
QUOL. A random subset of 12 patients from the
original group was then asked to complete the ques-
tionnaires for a second time at one month following
completion of the first and without any intervention
within that time period, to demonstrate reliability of
the scale. All interviews were conducted in person
by one of the authors (MS or EH) at RPH or in the
patients’ home. Table 1 shows patient characteristics.
Australian Vascular Quality of Life Index
The AUSVIQUOL (Fig. 2) was developed as a new
QOL index to be used specifically for patients suffering
from vascular disorders. It consists of ten questions
Eur J Vasc Endovasc Surg Vol 34, August 2007which are divided into three domains: General Health
Perceptions; Function, Mobility and Pain; and Psycho-
Social Aspects. Each question is scored using weighted
values which give a range of possible total scores from
zero (significant impairment in QOL within all
dimensions) to 100 (no impairment in QOL). Table 2
shows the QOL categories for the AUSVIQUOL. The
AUSVIQUOL has been demonstrated as a disease-
specific QOL appropriate for patients with AAA and
hence, may be appropriate for use throughout a range
of vascular surgical patients.
Medical Outcomes Short Form 36 Health Survey (SF-36)
The SF-36 was developed by Ware et al10 and designed
to assess the generic health concepts of QOL. As such,
it was not designed to be specific to age, disease or
treatment group.11 It includes 36 questions covering
eight domains: Bodily Pain, Physical Function, Physi-
cal Role Function, Mental Health, Vitality, Social
Function, Social Role Function, and General Health.
Responses to questions are either yes/no or in a scaled
score format. Scores are then used to calculate an
average score12 and transformed on a scale from zero
(very poor) to 100 (excellent).
Statistical analysis
(a) Study group
The validity of the AUSVIQUOL was assessed
through factor and regression analyses comparing
the domain scores of the AUSVIQUOL and SF-36.
For the factor analysis, all eleven domain scores across
the two scales [8 (SF-36) plus 3 (AUSVIQUOL)] were
analysed simultaneously in a single Maximum Like-
lihood Factor Analysis with a Promax rotation. The
Table 1. Patient characteristics of Study and Subset groups
Characteristic Study group (n¼ 71) Subset group (n¼ 12)
Mean age (years) 72.8 73.7
Gender
Male 48 8
Female 23 4
Table 2. QOL categories for the AUSVIQUOL
QOL Category Total score
Excellent 100
Very good 80e99
Good 55e79
Fair 21e54
Poor 0e20
201The AUSVIQUOL: Improved Clinical QOL Tool for PVDdomain scores were treated as a single set of scores to
identify which domains from each questionnaire were
related through underlying latent factors. For the
regressions analysis, the three domain scores from
the AUSVIQUOL were regressed individually against
the eight domain scores from the SF-36 to further
identify the relation between domain scores from
the two questionnaires. Each of the Regression analy-
ses was treated as an Ordinary Least Squares Multiple
Regression (MRA) and the method used was Stepwise
regression. The purpose of these analyses was to
determine the corresponding domain measures in
the SF-36 to each of the domain measures in the
AUSVIQUOL.
The internal consistency of each scale was assessed
with Cronbach’s alpha and was based on correlations
between domain scores for each scale.
(b) Subset group reassessment
A correlated t-test was carried out on the average
score of the SF-36 for the subgroup of 12 patients
who completed the two scales twice. Similarly, a corre-
lated t-test was conducted on the total score of the
AUSVIQUOL in the same group to ascertain whether
or not there was a change in scores over time, under
the expectation that there would be no change. In or-
der to reinforce this analysis given the small number
of cases and the possibility of anomalous data distri-
bution, a Bootstrap version of the Wilcoxon signed
ranks test was also used to test these differences.
Results
(a) Study group
The average time to complete the AUSVIQUOL and
SF-36 questionnaires was 3.27 (Range 2e9; SD 1.53)
and 10.79 (Range 7e22; SD 4.31) minutes respectively.
Thirty-six percent of patients required assistance com-
pleting both questionnaires as their reading glasses
were not available at the time. Twenty-six percent of
patients found questions confusing within the SF-36
compared to only 2% with the AUSVIQUOL. One
patient was unable to understand most of the ques-
tions in the SF-36. Comparison of the average score
of the SF-36 and the total score of the AUSVIQUOL
is presented in Fig. 1.
The factor analysis revealed two identifiable factors
which were interpreted as ‘Health and Physical Con-
dition’ and ‘Psychological State’. The pattern matrix is
displayed in Table 3. This shows that Factor 1 corre-
lates the Physical Function, Bodily Pain, Vitality, Gen-
eral Health and Role Physical domains of the SF-36with the Function, Mobility and Pain, and General
Health Perceptions domains of the AUSVIQUOL (Pat-
tern loading> 0.5); and Factor 2 correlates the Mental
Health, Role Emotional, and Social Function domains
of the SF-36 with the Psycho-Social Aspects domain
of the AUSVIQUOL (Pattern loading> 0.5). The
Goodness-of-Fit test was non-significant ( p¼ 0.620),
revealing that there were no more factors to extract
and the two factors fit the data without any significant
residual. The correlation between the two factors is
large (0.67), so much of the variance is shared between
the two factors.
The regression analysis, relating the domain scores
of the two questionnaires, showed that for each of the
domains in the AUSVIQUOL there was a significant
relation with domains in the SF-36. Some of the SF-
36 scores contained variance unrelated to the scores
in the AUSVIQUOL. In relation to General Health Per-
ceptions domain in the AUSVIQUOL, the General
Health domain of the SF-36 was significant and acco-
unted for 42% (adjusted) of the variance, as shown in
the regression equation GHP¼ 0.166GHþ 6.271.
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Fig. 1. Comparison of Average score of SF-36 with Total
score of AUSVIQUOL.
Table 3. Factor Analysis Pattern Matrix
Factor
Health and
Physical Condition
Psychological
State
Physical Function (SF-36) .958 .198
Function, Mobility
and Pain (AUSVIQUOL)
.758 .011
Bodily Pain (SF-36) .743 .022
Vitality (SF-36) .716 .249
General Health (SF-36) .641 .180
General Health
Perceptions (AUSVIQUOL)
.621 .023
Role Physical (SF-36) .510 .117
Mental Health (SF-36) .016 .887
Role Emotional (SF-36) .145 .861
Social Function (SF-36) .191 .588
Psycho-social Aspects
(AUSVIQUOL)
.156 .528
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Preliminary Details::  Name: Date of Birth:
Type of procedure:
1.  General Health Perceptions  
Q1 
1. Excellent
2. Very Good
3. Good
4. Fair
5. Poor
Q2
1. None
2. Between 1 and 5 days
3. Between 6 and 14 days
4. Between 15 and 30 days
5. Everyday
If you have had your vascular surgery, go to Q3a. If not, go to Q3b 
Q3a In comparison with your health before vascular surgery, how would you rate your health now? 
During the last month, how many days have you spent sick in bed?
How has your health been in the last month in comparison with other people you know of the same or similar age?
1. A lot better than before the surgery
2. A little better than before the surgery
3. The same as before the surgery
4. A little worse than before the surgery 
5. A lot worse than before the surgery
Q3b In comparison with your health 1 year ago, how would you rate your health now?  
1. A lot better than one year ago 
2. A little better than one year ago 
3. The same as one year ago 
4. A little worse than one year ago 
5. A lot worse than one year ago 
2. Function, Mobility and Pain
Q4 At a steady pace, how far are you able to walk on the flat before becoming short of breath, or experience chest pain, 
 leg pain or another limitation? 
1. More than 1km
2. Between 500m and 1km
3. Between 100m and 500m 
4. Between 1m and 100m
5. I can’t walk/I have pain at rest
Q5 Do you have pain or discomfort in your legs or feet that limits your mobility or disturbs your sleep, ulcers on your 
feet or have you lost a limb? 
1. None of these 
2. Leg or foot pain when I walk
3. Leg or foot pain at night 
4. I have an ulcer on my foot or leg
5. I’ve had a limb(s) amputated
Q6 Are you able to do most of the chores around the house and do your grocery shopping?  
1. Yes, easily
2. Yes, but I find it difficult
3. Yes, with some assistance
4. Yes, with continuous assistance 
5. No, not at all 
Fig. 2. The AUSVIQUOL.
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203The AUSVIQUOL: Improved Clinical QOL Tool for PVDDo you suffer from fits, faints, funny turns or memory problems (including epilepsy, transient ischaemic attack, episodes of
 dizziness, loss of consciousness or stroke)? 
Q7
1. Never/I used to/I had a non-disabling stroke
2. Occasionally 
3. Sometimes
4. Often
5. Continuously/I’ve had a disabling stroke  
Q8 Are you able to read a magazine or newspaper?
1. Yes, easily
2. Yes, but I find it difficult
3. Yes, with prescription glasses
4. No, but I still have some sight
5. No, I am blind  
3.  Psycho-Social Aspects 
Q9 How often do you see your friends and relatives, or participate in hobbies? 
1. Everyday
2. Several times per week
3. Once per week
4. Several times per month 
5. Rarely/Never
Q10 Have you felt lonely, unhappy, depressed, or anxious over the past month?
In general, have there been any changes in your life that you feel have been detrimental to your quality of life  (For example, are
there some things you can’t do anymore?)
1. No
2. Yes, occasionally
3. Yes, sometimes
4. Yes, often
5. All the time 
SCORING (Q1-10): 
Response 1 = 10 POINTS, 2 = 5 POINTS, 3 = 2 POINTS, 4 = 1 POINT, 5 = 0 POINTS.
Doimain Score: General Health Perceptions …/30 
Function, Mobility and Pain …/50 
Psycho-social Aspects …/20 
Total Score: …/100 
This person’s quality of life is: Total score 
Excellent 100 
Very Good 80-99 
Good 55-79 
Fair 21-54 
Poor 0-20 
Fig. 2. (Continued)For the Function, Mobility and Pain domain in the
AUSVIQUOL, two measures were significant in the
SF-36. Vitality accounted for 43% of the variance and
Physical Function added a further 5%. The total vari-
ance of Function, Mobility and Pain accounted for byboth measures was 48% (adjusted) and is represented
by the equation FMP¼ 0.174Vþ 0.157 PFþ 10.57.
The AUSVIQUOL’s Psycho-Social Aspects domain
was associated with the Mental Health domain of
the SF-36 (adjusted R-squared 0.331). Hence,
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correlated with the relevant domains of the SF-36
which provides evidence of construct validity.
For all three of the regression analyses the power
was sufficient to reject H0: R
2¼ 0. The value of a single
degree of freedom DR2 that could be detected in the
first analysis while maintaining a¼ 0.05, b¼ 0.2 and
N¼ 71 was 0.06, for the second analysis it was also
0.06, and for the third analysis it was 0.08.12 For
each of the regression analyses the variables not
included in the reported regression equations only
accounted for trivial non-significant increments in R2.
Internal consistency on domain scores within the
AUSVIQUOL according to Cronbach’s Alpha revealed
a good level of internal consistency (Alpha¼ 0.8702).
In comparison, the internal consistency for the SF-36
was just acceptable (Alpha¼ 0.6307). These results
support proceeding to test time 1 and 2 differences.
(b) Subset group reassessment
The correlated t-test of the average score for the SF-36
and the total score for the AUSVIQUOL showed that
differences between the first and second assessments
were not significant for either the SF-36 or the AUSVI-
QUOL demonstrating evidence of test-retest reliabil-
ity for both measures (See Table 4). The bootstrap
version of the Wilcoxon signed ranks test also showed
no significant change for either scale between time 1
and time 2. A Wilcoxon paired ranks test could only
reliably detect large difference effect sizes of the order
f¼ 0.89 (mean difference/standard error difference).
This is the effect size required to detect a difference
for a t-test on the data at a¼ 0.05 (1-tailed), b¼ 0.2
and n¼ 12.13 The power of Wilcoxon test approxi-
mates that of the t-test adjusted by its asymptotic
relative efficiency 3/p. The adjusted observed effect
size14,15 was approximately f¼ 0.02 based on the stan-
dard Wilcoxon test for the first comparison (average
score of SF-36, time 1 vs time 2). In this instance it is
clearly low powered. The power of the bootstrap
Table 4. Correlated t-test distribution data
Mean N Std.
deviation
Std.
error
mean
SF-36 Average score
e Time 1
64.0741 12 12.44225 3.59177
Average score
e Time 2
63.8657 12 16.27311 4.69764
AUSVIQUOL Total score
e Time 1
58.92 12 8.163 2.356
Total score
e Time 2
58.4167 12 12.39837 3.57910
Eur J Vasc Endovasc Surg Vol 34, August 2007version would exceed this value, however, would still
be low. The actual value cannot be determined with-
out running a large Monte Carlo simulation, but it is
likely to be of the same order of magnitude. Notwith-
standing the low power of the test in this application,
the observed effect size associated with the t-test is
trivial and any potential but undetected real differ-
ence between times 1 and 2 is also likely to be small.
A similar analysis for the second test (total score of
AUSVIQUOL, time 1 vs time 2) shows an even
smaller observed effect size. Thus one can be reason-
ably confident that any real differences between
time 1 and 2 data are small.
Discussion
The present study was conducted to validate a new
vascular disease QOL instrument for use in individ-
uals with intermittent claudication suitable for use
in the clinical setting. In contrast to the SF-36, the cur-
rent gold standard QOL measure,16 the AUSVIQUOL
focuses on symptoms and problems specifically rela-
ted to vascular disease. The AUSVIQUOL was ini-
tially validated in AAA patients;9 it has now been
assessed for its appropriateness for use in patients
with vascular claudication with encouraging results.
The AUSVIQUOL was more acceptable for this
group of patients for a variety of reasons. It is signif-
icantly less time-consuming and overall less confus-
ing than the SF-36. It is easier to administer and has
a higher level of patient acceptance, and is also
more relevant and less repetitive than the SF-36. It
includes specific symptoms that are experienced by
vascular patients and excludes question areas cover-
ing less common or irrelevant symptomatology. These
make it more appropriate for an elderly population
and easier to administer from a research perspective.
The factor analysis showed the AUSVIQUOL to be
a valid QOL measure for vascular claudication
patients. It revealed two identifiable factors which
related comparable domains of each questionnaire.
The regression analysis revealed that conceptually
related domains of the AUSVIQUOL and SF-36 were
significantly related, which provides evidence of
construct validity. The internal consistency of the
AUSVIQUOL was found to be good.
The subset group reassessment demonstrated test-
retest reliability for bothmeasures.As the reassessment
was made at one month following the first assessment
and therewas no interventionmade during this period,
it was reassuring that there was no significant differ-
ence between the assessment scores in either the
SF-36 or the AUSVIQUOL.
205The AUSVIQUOL: Improved Clinical QOL Tool for PVDThe Claudication Scale (CLAU-S) and the King’s
College Hospital’s Vascular Quality of Life Question-
naire (VascuQol) are both measures specifically
targeted at the QOL of claudicants. The CLAU-S,
developed in Germany in 1995, is one of the earliest
disease-specific measures for intermittent claudica-
tion. The VascuQol, developed in London in 2000,
was designed to cover a spectrum of chronic lower
limb ischaemia rather than claudication alone.3 The
VascuQol has been shown to be a more sensitive mea-
sure than the CLAU-S for claudicants.4,6 It comprises
of 25 questions across 5 domains; Pain, Symptoms,
Activities, Social and Emotional.3 Averaged scores
range from 1 (worst QOL) to 7 (best QOL).3 While
the purpose of this study was to compare the AUSVI-
QUOL with the current ‘gold standard’ QOL tool, the
SF-36, a comparison of the AUSVIQUOL with the
VascuQol for peripheral vascular disease patients
will be the subject for future research.
Peripheral vascular disease rarely occurs in isola-
tion; often these patients are ‘vasculopaths’ with con-
comitant cardio- and cerebro-vascular or aneurysmal
disease. Neither the CLAU-S nor the VascuQol take
this into consideration. The AUSVIQUOL has been
developed to bridge this gap and to provide a global
assessment of the vasculopath. The AUSVIQUOL has
been designed to provide valuable information to the
clinician in the clinical as well as in a research
setting.
The successful use of the AUSVIQUOL in AAA
patients as well as those with intermittent claudica-
tion suggests that it will be appropriate for use in
all areas of vascular surgery. Further evaluation
and assessment in patients with cerebrovascular
and cardiovascular disease will be conducted in the
future.
As the AUSVIQUOL has compared favourably
with the SF-36 across two populations of patients
(AAA patients and now peripheral vascular disease
patients), we feel that the AUSVIQUOL could be rec-
ommended for use without an accompanying generic
measure for vascular disease patients.
In conclusion, the benefits of the AUSVIQUOL is
that its simplicity and short self-administration time
make it very appropriate for use in patient waiting
areas, outpatient clinics and private rooms. The
domain and overall scores can be calculated such
that is amenable to both research and clinical use.Acknowledgements
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